Please use this identifier to cite or link to this item:
|Title:||Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalities||Authors:||Jimenez-Zepeda, V.H.
|Keywords:||Chromosome banding analysis
Chronic lymphocytic leukemia (CLL)
|Issue Date:||Aug-2013||Citation:||Jimenez-Zepeda, V.H., Chng, W.J., Schop, R.F.J., Braggio, E., Leis, J.F., Kay, N., Fonseca, R. (2013-08). Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalities. Clinical Lymphoma, Myeloma and Leukemia 13 (4) : 467-476. ScholarBank@NUS Repository. https://doi.org/10.1016/j.clml.2013.05.003||Abstract:||Background: A major conclusion drawn from the accumulated cytogenetic data on solid tumors and some hematologic malignancies is that tumors progress by the acquisition of chromosomal changes, as reflected by more aggressive tumors containing a larger number of chromosomal abnormalities. An additional observation is that some chromosomal changes appear early in the disease progression, and some others appear late. Material and Methods: On the basis of this information, a model for karyotypic evolution in chronic lymphocytic leukemia (CLL) is presented. The Mitelman Database of Chromosomes in Cancer was searched, and 1749 abnormal karyotypes were assessed. The main clones were analyzed, and chromosomal gains and losses were used to design a model of genetic acquisition based on the calculation of a variable called time to occurrence (TO). Results: Our comprehensive study of genetic abnormalities in a large number of CLL karyotypes revealed that most CLL has 2 chromosomal aberrations at diagnosis. Moreover, the temporal analysis suggests that trisomy 12 is an early event in the biological evolution of CLL. Conclusion: These results highlight the possibility of targeted therapies affecting the genes located on this chromosome (cyclin D, cyclin D2, cyclin-dependent kinase 2, and cyclin-dependent kinase 4). © 2013 Elsevier Inc. All rights reserved.||Source Title:||Clinical Lymphoma, Myeloma and Leukemia||URI:||http://scholarbank.nus.edu.sg/handle/10635/126844||ISSN:||21522650||DOI:||10.1016/j.clml.2013.05.003|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Mar 21, 2023
WEB OF SCIENCETM
checked on Mar 21, 2023
checked on Mar 16, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.